Remus Pharmaceuticals Ltd.
REMUS.NS · National Stock Exchange of India · INR
820,50INR
+5,50 (+0,67 %)Stand 9. Nov., 9:58
Kennzahlen
- Eröffnung
- 816,00
- Vortag
- 815,00
- Tagesspanne
- 814,50 – 825,00
- 52 Wochen
- 580,00 – 1.039,00
- Volumen
- 1800
- Ø Volumen
- 9321
- Börsenwert
- 9,67 Mrd. INR
- KGV
- –
- Gewinn je Aktie (TTM)
- –
- Dividendenrendite
- –
- Beta
- 0,2
- Nächste Zahlen
- –
Finanzen
Gerade nicht verfügbar.
Bewertung
Gerade nicht verfügbar.
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
Gerade nicht verfügbar.
Dividenden und Splits
Gerade nicht verfügbar.
Aktiensplits
Gerade nicht verfügbar.
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
Gerade nicht verfügbar.
Vergleichbare Unternehmen
Gerade nicht verfügbar.
Über das Unternehmen
Remus Pharmaceuticals Ltd. is a pharmaceutical company engaged in the marketing, trading, and distribution of finished dosage formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company's diverse product portfolio, exceeding 600 offerings, includes tablets, capsules, injections, creams, gels, eye drops, and various other dosage forms. Remus Pharmaceuticals focuses on therapeutic categories such as Critical Care, Oncology, Nephrology, Central Nervous System, Cardiology, Diabetics, Antibiotics, Immunosuppressants, Anti-inflammatory, Antifungal, Antipsychotic, Antiretroviral, Dermatology, Urology, and products for vitamin deficiency. The company primarily targets export markets, with significant operations in the Middle East, Africa, Southeast Asia, Latin America, and other emerging global markets. Leveraging an asset-light business model, Remus Pharmaceuticals collaborates with third-party and contract manufacturers, while also possessing manufacturing capabilities in India and the USA, to produce and distribute cost-effective generic alternatives. Additionally, the company provides technical and consultancy services for preparing product dossiers for international registration and engages in research and development for generic drugs and clinical trials.
- CEO
- Arpit Deepakkumar Shah
- Mitarbeitende
- 69
- Hauptsitz
- Ahmedabad, GU, IN
- Sektor
- Healthcare
- Branche
- Medical - Pharmaceuticals
- Börsengang
- 29. Mai 2023
- Website
- remuspharma.com/investors
Nachrichten
Gerade nicht verfügbar.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.